Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bright Minds Biosciences Inc (DRUG.CN)

Bright Minds Biosciences Inc (DRUG.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 516,124
  • Shares Outstanding, K 7,089
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,802 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta -4.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.96

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.8500 +15.81%
on 11/04/25
96.5000 -13.77%
on 10/17/25
-3.7900 (-4.36%)
since 10/10/25
3-Month
53.9900 +54.12%
on 09/03/25
96.5000 -13.77%
on 10/17/25
+29.6400 (+55.33%)
since 08/08/25
52-Week
33.0100 +152.08%
on 06/30/25
96.5000 -13.77%
on 10/17/25
+17.8400 (+27.29%)
since 11/08/24

Most Recent Stories

More News
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH

-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prader-Willi...

DRUG : 59.30 (+0.87%)
DRUG.CN : 83.2100 (+14.28%)
Bright Minds Biosciences to Present at Upcoming Conferences

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective...

DRUG : 59.30 (+0.87%)
DRUG.CN : 83.2100 (+14.28%)
BRIGHT MINDS BIOSCIENCES ANNOUNCES AT-THE-MARKET OFFERING

/CNW/ - Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") announces that it has entered into an equity distribution...

DRUG : 59.30 (+0.87%)
DRUG.CN : 83.2100 (+14.28%)
Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG) today announced compelling preclinical results for its investigational compound BMB‑201, in a validated isosorbide...

DRUG : 59.30 (+0.87%)
DRUG.CN : 83.2100 (+14.28%)
Bright Minds Biosciences to Present at Upcoming Conferences

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective...

DRUG : 59.30 (+0.87%)
DRUG.CN : 83.2100 (+14.28%)
Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

DRUG : 59.30 (+0.87%)
DRUG.CN : 83.2100 (+14.28%)
Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

DRUG : 59.30 (+0.87%)
DRUG.CN : 83.2100 (+14.28%)
Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101

DRUG : 59.30 (+0.87%)
DRUG.CN : 83.2100 (+14.28%)
Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

DRUG : 59.30 (+0.87%)
DRUG.CN : 83.2100 (+14.28%)
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

DRUG : 59.30 (+0.87%)
DRUG.CN : 83.2100 (+14.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders...

See More

Key Turning Points

3rd Resistance Point 72.8100
2nd Resistance Point 72.8100
1st Resistance Point 72.8100
Last Price 83.2100
1st Support Level 72.8100
2nd Support Level 72.8100
3rd Support Level 72.8100

See More

52-Week High 96.5000
Last Price 83.2100
Fibonacci 61.8% 72.2468
Fibonacci 50% 64.7550
Fibonacci 38.2% 57.2632
52-Week Low 33.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar